AU785133B2 - Molecular clones with mutated HIV GAG/POL, SIV GAG and SIV ENV genes - Google Patents

Molecular clones with mutated HIV GAG/POL, SIV GAG and SIV ENV genes Download PDF

Info

Publication number
AU785133B2
AU785133B2 AU25923/01A AU2592301A AU785133B2 AU 785133 B2 AU785133 B2 AU 785133B2 AU 25923/01 A AU25923/01 A AU 25923/01A AU 2592301 A AU2592301 A AU 2592301A AU 785133 B2 AU785133 B2 AU 785133B2
Authority
AU
Australia
Prior art keywords
gag
hiv
gene
cells
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU25923/01A
Other languages
English (en)
Other versions
AU2592301A (en
Inventor
George N Pavlakis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of AU2592301A publication Critical patent/AU2592301A/en
Application granted granted Critical
Publication of AU785133B2 publication Critical patent/AU785133B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU25923/01A 1999-12-23 2000-12-22 Molecular clones with mutated HIV GAG/POL, SIV GAG and SIV ENV genes Expired AU785133B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17303699P 1999-12-23 1999-12-23
US60/173,036 1999-12-23
PCT/US2000/034985 WO2001046408A2 (en) 1999-12-23 2000-12-22 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes

Publications (2)

Publication Number Publication Date
AU2592301A AU2592301A (en) 2001-07-03
AU785133B2 true AU785133B2 (en) 2006-10-05

Family

ID=22630264

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25923/01A Expired AU785133B2 (en) 1999-12-23 2000-12-22 Molecular clones with mutated HIV GAG/POL, SIV GAG and SIV ENV genes

Country Status (8)

Country Link
EP (2) EP2128256B1 (cg-RX-API-DMAC10.html)
JP (1) JP4627950B2 (cg-RX-API-DMAC10.html)
AT (1) ATE438714T1 (cg-RX-API-DMAC10.html)
AU (1) AU785133B2 (cg-RX-API-DMAC10.html)
CA (1) CA2395269C (cg-RX-API-DMAC10.html)
DE (1) DE60042702D1 (cg-RX-API-DMAC10.html)
ES (2) ES2329648T3 (cg-RX-API-DMAC10.html)
WO (1) WO2001046408A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US6656706B2 (en) * 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2003095605A2 (en) * 2002-05-08 2003-11-20 Pharmacia Italia Spa A chimeric reverse transcriptase and methods for identifying telomerase inhibitors
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB201501523D0 (en) * 2015-01-30 2015-03-18 Univ Plymouth Differential immune response modulation
US11820999B2 (en) * 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972596A (en) * 1992-03-27 1999-10-26 The United States Of America As Represented By The Department Of Health And Human Services Nucleic acid constructs containing HIV genes with mutated inhibitory/instability regions and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69938044T2 (de) * 1998-05-22 2009-01-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Neue post-transkriptionelle regulationselemente und deren verwendung
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU778106B2 (en) * 1999-04-26 2004-11-18 K.U. Leuven Research & Development Synthetic gene for expressing active retroviral protein in eukaryotes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972596A (en) * 1992-03-27 1999-10-26 The United States Of America As Represented By The Department Of Health And Human Services Nucleic acid constructs containing HIV genes with mutated inhibitory/instability regions and methods of using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
QIU, J.T. ET AL, 1999, JOURNAL OF VIROLOGY, 73:9145-9152 *
SCHWARTZ, S. ET AL, 1992, JOURNAL OF VIROLOGY, 66:7176-7182 *

Also Published As

Publication number Publication date
CA2395269A1 (en) 2001-06-28
EP1246913B1 (en) 2009-08-05
AU2592301A (en) 2001-07-03
WO2001046408A3 (en) 2001-12-13
EP2128256A3 (en) 2009-12-23
EP1246913A2 (en) 2002-10-09
JP4627950B2 (ja) 2011-02-09
ATE438714T1 (de) 2009-08-15
JP2003517839A (ja) 2003-06-03
WO2001046408A9 (en) 2002-11-07
ES2329648T3 (es) 2009-11-30
EP2128256B1 (en) 2013-06-26
EP2128256A2 (en) 2009-12-02
CA2395269C (en) 2015-12-08
DE60042702D1 (de) 2009-09-17
WO2001046408A2 (en) 2001-06-28
ES2420842T3 (es) 2013-08-27

Similar Documents

Publication Publication Date Title
US7608422B2 (en) Simian immunodeficiency virus (SIV) molecular clone encoding mutant gag gene lacking inhibitory/instability regions
CN1840204B (zh) 用于制备免疫治疗性组合物的慢病毒载体
AU2002303934A1 (en) Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
US7056699B2 (en) Lentiviral LTR-deleted vector
JP4571306B2 (ja) ヌクレオチド配列の導入のためのトリプレックス構造のｄｎａ配列の利用
AU729231B2 (en) Synthetic HIV genes
US20030229214A1 (en) Vaccines comprising synthetic genes
AU2002228722B2 (en) Expression vectors able to elicit improved immune response and methods of using same
JP2001512308A (ja) 合成ｈｉｖ ｇａｇ遺伝子
JPH11512615A (ja) 非分裂細胞への核酸運搬のためのベクターおよび使用方法
CA2258568A1 (en) Vaccines comprising synthetic genes
JP2001502903A (ja) レンチウィルスベクター
JP2001502539A (ja) レトロウイルスベクター
US20230364216A1 (en) Lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses in a host
JP2018183165A (ja) レンチウイルスパッケージ化のための非サブタイプｂのｇａｇタンパク質の使用
EP1246913B1 (en) Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
NZ525283A (en) Conditionally replicating vectors, methods for their production and use
US20030026791A1 (en) Conditionally replicating vectors for inhibiting viral infections
WO2002079464A2 (en) Viral vectors
US20030087225A1 (en) Synthetic HIV genes
MXPA98006842A (en) Synthetic genes of
AU2002249393A1 (en) Viral vectors
HK1149289A (en) Use of lentiviral triplex forming sequences for nuclear transfer of nucleotide sequences

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired